Literature DB >> 8207225

Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis.

F Mokhtarian1, Y Shi, D Shirazian, L Morgante, A Miller, D Grob.   

Abstract

Activated T lymphocytes play an important role in the pathogenesis of multiple sclerosis (MS). These T cells secrete both pro- and anti-inflammatory cytokines. We have studied the production of these two kinds of cytokines by PBL of patients with MS and compared it with normal controls and other autoimmune diseases (OAD). PBL of 29 patients with MS, 14 patients with OAD, and 14 healthy normal controls were cultured for 5 wk. PBL of MS patients produced more pro-inflammatory cytokines, IL-2, IFN-gamma and TNF/lymphotoxin, and less anti-inflammatory cytokine, TGF-beta, during wk 2 to 4 in culture than PBL of normal controls. PBL of MS patients also produced more IL-2 and TNF/lymphotoxin than PBL of OAD patients. Decreased TGF-beta production by lymphocytes of patients with MS correlated directly with disease activity. MS patients with active disease produced less TGF-beta than MS patients with stable disease. The cells producing TGF-beta were primarily CD8+ T cells and CD45RA+T cells. These findings emphasize the complexity of immune response in MS patients and suggest that the increased production of pro-inflammatory cytokines by lymphocytes of patients with MS, combined with the decreased production of TGF-beta (anti-inflammatory cytokine), may play an important role in the mechanisms and manifestations of MS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207225

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Correlation between interferon production and clinical disease activity in patients with multiple sclerosis.

Authors:  M Dettke; P Scheidt; H Prange; H Kirchner
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

3.  TGF-β signaling is altered in the peripheral blood of subjects with multiple sclerosis.

Authors:  Elise M Meoli; Unsong Oh; Christian W Grant; Steven Jacobson
Journal:  J Neuroimmunol       Date:  2010-11-19       Impact factor: 3.478

4.  Time-dependent increases in protease activities for neuronal apoptosis in spinal cords of Lewis rats during development of acute experimental autoimmune encephalomyelitis.

Authors:  Arabinda Das; M Kelly Guyton; Denise D Matzelle; Swapan K Ray; Naren L Banik
Journal:  J Neurosci Res       Date:  2008-10       Impact factor: 4.164

5.  TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10.

Authors:  David J Huss; Ryan C Winger; Haiyan Peng; Yuhong Yang; Michael K Racke; Amy E Lovett-Racke
Journal:  J Immunol       Date:  2010-04-14       Impact factor: 5.422

6.  Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients.

Authors:  S Inogés; J Merino; E Bandrés; P De Castro; M L Subirá; A Sánchez-Ibarrola
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 7.  Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection.

Authors:  Shomyseh Sanjabi; Soyoung A Oh; Ming O Li
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-06-01       Impact factor: 10.005

8.  The rs3761548 FOXP3 variant is associated with multiple sclerosis and transforming growth factor β1 levels in female patients.

Authors:  Tamires Flauzino; Daniela Frizon Alfieri; Wildea Lice de Carvalho Jennings Pereira; Sayonara Rangel Oliveira; Ana Paula Kallaur; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Karen Brajão de Oliveira; Andrea Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Inflamm Res       Date:  2019-08-14       Impact factor: 4.575

9.  Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1.

Authors:  L Z Chen; G M Hochwald; C Huang; G Dakin; H Tao; C Cheng; W J Simmons; G Dranoff; G J Thorbecke
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

10.  Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).

Authors:  F Nicoletti; R Di Marco; F Patti; E Reggio; A Nicoletti; P Zaccone; F Stivala; P L Meroni; A Reggio
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.